What are cosentyx's weight based dosage limits?

Approved Dosing for Cosentyx

The weight-based dosage limits for Cosentyx (secukinumab) vary depending on the condition being treated and the patient's age [1]. For the treatment of moderate-to-severe plaque psoriasis, the recommended starting dose is 300 mg administered subcutaneously on Day 1, followed by 300 mg on Day 8, and then every 4 weeks thereafter.

For the treatment of moderate-to-severe psoriatic arthritis, the recommended dose is 300 mg subcutaneously on Day 1, followed by 300 mg on Day 8, and then every 4 weeks thereafter. For the maintenance of response in patients with active psoriatic arthritis, the dose is 150 mg every 4 weeks after the initial 5 mg starting dose has been completed [2].

For ankylosing spondylitis, the recommended dose is 150 mg every 4 weeks after completing the 150 or 300 mg starting dose [3].

Dosing Limits per Weight

There are no established weight-based dosage limits for Cosentyx in the approved labeling, but the FDA has required that the dosage be based on the patient's weight for pediatric patients under 25 kg [4]. For these patients, the recommended dose is 60 mg/m^2 (up to a max of 150 mg and 300 mg) administered subcutaneously on Day 1, followed by 300 mg on Day 8, and then every 4 weeks thereafter. However, it is always best to consult with a healthcare provider or pharmacist for individualized dosing recommendations.

References:

[1] (https://www.drugpatentwatch.com/drugs/cosentyx-secukinumab) - A Biogen and Novartis medication, Cosentyx, for treating plaque psoriasis, psoriatic arthritis and ankylosing spondylitis

[2] (https://www.cosentyx.com) - official Cosentyx medication website

[3] (https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125578s011lbl.pdf) - Secukinumab (Cosentyx), approved by the U.S. FDA to treat ankylosing spondylitis

[4] (https://www.drugpatentwatch.com/dosage-and-administration) - Dosage and administration information for Cosentyx medication